Vintura Adds Tim Wartenberg As Partner For Germany Branch

Vintura, a Dutch consulting firm focused on life sciences and healthcare, has recently announced a new addition to its team of partners in the company’s Germany branch.

Tim Wartenberg is a 25-year veteran in the industry of consultancy and has an abundance of experience to offer Vintura. He began his career in the pharmaceutical industry, working mostly in sales, marketing, and distribution before moving on in 2003 to start his own business. He ran that advisory firm for eight years, building the employee count to 15 before selling and moving to other consulting firms.

He then served in the healthcare and life science divisions of multiple consulting firms, including working as the European lead of the Life Science Practice at Infosys Consulting and being partner at Monitor Deloitte.

Throughout this period of Wartenberg’s career, he also served a handful of important pharmaceutical clients such as Bauer, Lonza, Novartis, Boehronger Ingelhein, and more. He specialized in providing services ranging from market access, patient advocacy, and strategy to digitization, management, and system implementation.

This special combination of experience makes him a welcome asset to the Vintura team, where he will be dealing with clients from the healthcare industry on a regular basis.“We are glad to have Tim join our team. He truly reflects our drive to create remarkable impact in healthcare together. Under his leadership, we are convinced the Munich office will further expand and flourish,” said Bas Amesz, a Netherlands-based partner at Vintura.

Vintura has expanded its presence in Europe since its initial founding in 2000 in the Netherlands, and is currently hoping to tackle the German market with greater force, hence the addition of new partners to this branch. In addition to Germany, the company is also seeking expansion into the United Kingdom.

The company has many high-profile clients including AbbVie, Amgen, Ferring, Genzyme, Ipsen, Janssen, Johnson & Johnson, Medtronic, Roche, Sanofi and Takeda.